Hospitalization after primary cadaveric kidney transplantation: Difference between neoral and tacrolimus-based regimens.

被引：0
|
作者：
Chareandee, C [1 ]
Fink, J [1 ]
Klassen, D [1 ]
Weir, M [1 ]
Bartlett, S [1 ]
机构：
[1] Univ Maryland, Div Nephrol & Transplantat, Baltimore, MD 21201 USA
来源：
TRANSPLANTATION | 1999年 / 67卷 / 07期
关键词：
D O I：
10.1097/00007890-199904150-00589
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
563
引用
收藏
页码：S147 / S147
页数：1
相关论文
共 50 条
  • [1] Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus-based regimens
    Wlodarczyk, Z
    Walaszewski, J
    Perner, F
    Vitko, S
    Ostrowski, M
    Bachleda, P
    Kokot, F
    Klinger, M
    Szenohradszky, P
    Studenik, P
    Navratil, P
    Asztalos, L
    Rutkowski, B
    Kalmar, KN
    Hickey, D
    TRANSPLANT INTERNATIONAL, 2005, 18 (02) : 157 - 162
  • [2] National transplantation pregnancy registry:: Pregnancy outcomes in female kidney recipients treated with neoral→ vs. tacrolimus based regimens.
    Armenti, VT
    Coscia, LA
    Dunn, SR
    Radomski, JS
    Wilson, GA
    Moritz, MJ
    TRANSPLANTATION, 2000, 69 (08) : S322 - S322
  • [3] Cardiovascular and metabolic complications after liver transplantation: Neoral- versus tacrolimus-based immunosuppression
    Risaliti, A
    Baccarani, U
    Vianello, V
    Donini, A
    Adani, GL
    Sainz, M
    Montanaro, D
    Alessandrini, V
    Bresadola, F
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (7-8) : 3684 - 3685
  • [4] Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation
    Bhorade, SM
    Jordan, A
    Villanuev, J
    Yu, A
    Kramer, H
    Vigneswaran, WT
    Garrity, ER
    AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (12) : 1570 - 1575
  • [5] Donor Specific Antibody (DSA) Formation in Tacrolimus-Based, Mycophenolate vs mTOR Immunosuppression Regimens.
    Mithani, Z.
    Adebiyi, O.
    Gralla, J.
    Klem, P.
    Cooper, J.
    Wiseman, A.
    TRANSPLANTATION, 2014, 98 : 543 - 543
  • [6] Outcomes in Kidney Transplant Recipients after Conversion from Tacrolimus to Belatacept-Based Regimens.
    Underwood, H.
    Lange, N.
    Hedvat, J.
    Brennan, C.
    Tsapepas, D.
    King, K.
    Husain, S.
    Salerno, D.
    Patel, S.
    Mohan, S.
    Crew, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 697 - 697
  • [7] Tacrolimus vs CyA neoral in combination with MMF and steroids after cadaveric renal transplantation
    Wang, XH
    Tang, XD
    Xu, D
    TRANSPLANTATION PROCEEDINGS, 2000, 32 (07) : 1702 - 1703
  • [8] Tacrolimus-based immunosuppressive therapy for cadaveric renal transplantation: Two cases report
    Hasumi, M
    Hatori, M
    Kato, Y
    Tanaka, T
    Matsuo, Y
    Sekihara, T
    Machida, M
    Hayashi, M
    Yamanaka, H
    JAPANESE JOURNAL OF TRANSPLANTATION, 1998, 33 (04) : 288 - 294
  • [9] Impact of a sirolimus/tacrolimus-based immunosuppressive regimen on kidney function after islet transplantation
    Andres, A
    Toso, C
    Morel, P
    Demuylder-Mischler, S
    Bosco, D
    Baertschiger, R
    Pernin, N
    Bucher, P
    Majno, PE
    Bühler, LH
    Berney, T
    TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) : 1326 - 1327
  • [10] TACROLIMUS-BASED IMMUNOSUPPRESSION ONLY MARGINALLY AFFECTS MONOCYTE ACTIVATION AFTER KIDNEY TRANSPLANTATION
    Kannegieter, Nynke
    Hesselink, Dennis
    Dieterich, Marjolein
    De Graav, Gretchen
    Kraaijeveld, Rens
    Rowshani, Ajda
    Leenen, Pieter
    Baan, Carla
    TRANSPLANT INTERNATIONAL, 2017, 30 : 476 - 476
12345